50,000 Shares in Benitec Biopharma Inc. (NASDAQ:BNTC) Purchased by MYDA Advisors LLC

MYDA Advisors LLC bought a new position in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 50,000 shares of the biotechnology company's stock, valued at approximately $632,000. MYDA Advisors LLC owned about 0.22% of Benitec Biopharma at the end of the most recent reporting period.

Separately, Geode Capital Management LLC lifted its holdings in shares of Benitec Biopharma by 31.3% in the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company's stock worth $772,000 after acquiring an additional 20,012 shares during the last quarter. Institutional investors own 52.19% of the company's stock.

Insider Activity

In related news, Director Suvretta Capital Management, L bought 900,000 shares of the company's stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average cost of $13.00 per share, with a total value of $11,700,000.00. Following the transaction, the director now owns 8,793,245 shares in the company, valued at approximately $114,312,185. This trade represents a 11.40 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.30% of the company's stock.

Analyst Ratings Changes

BNTC has been the topic of several recent research reports. JMP Securities lifted their target price on shares of Benitec Biopharma from $18.00 to $20.00 and gave the stock a "market outperform" rating in a research report on Thursday, April 10th. HC Wainwright reaffirmed a "buy" rating and set a $28.00 price objective on shares of Benitec Biopharma in a research note on Monday, March 24th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $24.71.

Benitec Biopharma Trading Down 0.1 %

Shares of BNTC stock traded down $0.02 during mid-day trading on Tuesday, reaching $13.78. The stock had a trading volume of 34,167 shares, compared to its average volume of 41,424. The firm has a market capitalization of $323.15 million, a PE ratio of -9.13 and a beta of 0.76. The stock's 50-day moving average price is $12.95 and its two-hundred day moving average price is $11.61. Benitec Biopharma Inc. has a 52-week low of $5.74 and a 52-week high of $16.90.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last announced its quarterly earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.19. On average, equities research analysts forecast that Benitec Biopharma Inc. will post -1.48 earnings per share for the current year.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.